Charles River Labs Q4 GAAP loss $(4.22) on $215M goodwill impairment; guides FY2025 revenue down 5.5-3.5%

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

2024-FY EPS reported $0.20 revenue$4,049,989,000

Q4 revenue $1.00B (-1.1% YoY); non-GAAP EPS $2.66 (+8.1%); GAAP loss $(4.22) from $215M Biologics Solutions goodwill impairment.
Full-year 2024 revenue $4.05B (-1.9%); non-GAAP EPS $10.32 (-3.3%); GAAP EPS $0.20 (-97.8%).
DSA segment revenue down 3.6% organically; Manufacturing organic +2.1%; RMS organic -0.4% despite Noveprim acquisition.
2025 guidance: organic revenue decline 5.5% to 3.5%; non-GAAP EPS $9.10-$9.60; plans $350M stock repurchase.
CEO cites ongoing biopharma client restructuring; expects stable-to-slightly improved biotech demand in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.